Life sciences consultancy Kymanox hires Tony Perry as CFO

26 November 2021 2 min. read

Kymanox, a Raleigh, NC-based life sciences consulting firm, has hired Tony Perry as chief financial officer.

Perry brings more than 17 years of experience in finance and accounting, with significant financial executive experience in the life sciences sector. As CFO of Kymanox, he will oversee the firm’s financial strategy and operations, including accounting and financial reporting, M&A, tax, treasury, risk management, and budgeting and planning.

Perry will join the firm’s executive leadership team and will report to Kymanox CEO Stephen Perry (no relation).

Perry previously spent more than six years at TrialCard, a provider of enterprise management solutions to biopharmaceutical firms, where he served as senior vice president of finance. At TrialCard, he oversaw financial reporting strategy during a period of rapid growth and helped the firm grow via expansion and acquisition.

Before that, he was director of finance at Health Decisions, a clinical research organization, and VP of accounting and finance at Care Services, a provider of pharmacy benefits management, pharmacy services, and delivery logistics to the long-term care industry. Perry was also previously controller of Clinverse, a technology firm focusing on the financial management of clinical trials and related payments.

Life sciences consultancy Kymanox hires Tony Perry as CFO

Earlier in his career, Perry was an audit supervisor at accounting firm Frost and a senior accountant at TRP CPAs.

He holds a master’s degree in accountancy from Wake Forest University and a bachelor’s degree in accounting and information systems from Virginia Tech. Perry is also a licensed CPA.

“I am thrilled to join Kymanox during this exciting time of growth and expansion,” Tony Perry said. “Our organization is poised for continued success with a plan to grow even faster in Fiscal Year 2022. With our added capabilities and ongoing infrastructure investments, we are better able to serve our clients and help them succeed when addressing quality, engineering, and product development challenges that arise when bringing products to market.”

Kymanox achieved growth of 45% in fiscal year 2021 as demand for consulting services in the life sciences industry accelerated in the pandemic era.

Kymanox’s consultants deliver engineering, scientific, regulatory, and process operations support to clients in combination products, biologics, pharmaceuticals, and medical devices. The firm’s core competencies include project management, quality and compliance, technical operations, and validation.

The firm has more than 140 employees across offices in Raleigh, Boston, Chicago, and Branchburg, NJ, with an international location in Luxembourg.